Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

d to $16.2 million, or $0.77 per share, for the prior year period. The increase in the net loss from the prior year periods is due to a combination of lower revenue and higher spending due to increased clinical activities, headcount growth, and expenses related to research and development projects. The net loss for the prior year nine month period includes a cumulative benefit from the accounting change of adopting SFAS123(R) in January 2006 of approximately $0.3 million reflecting the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as permitted prior to 2006.

Research and development expenses for the current quarter increased $3.3 million to approximately $13.8 million as compared to the prior year period and increased $8.4 million to $39.4 million for the nine months ended September 30, 2007 from the prior year period. This year-to-date net increase reflects an actual increase of approximately $12.5 million in R&D expenditures, primarily due to increases in clinical activities, the number of research and development employees and related infrastructure costs. The prior year nine month period included a $4.1 million charge due to in-process R&D expenses related to our acquisition of RNAi intellectual property from Galenea Corp. in the first quarter 2006.

Selling, general and administrative expenses increased $1.6 million to approximately $5.1 million for the current quarter compared to the prior year quarter and increased $4.0 million to approximately $14.5 million for the nine months ended September 30, 2007 from the prior year period, primarily due to increases in patent and legal costs necessary to support our business model as well as our growth.

We ended the third quarter of 2007 with approximately $58.1 million in cash, cash equivalents and investments compared to $51.0 million at December 31, 2006, including $2.2 mill
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Del. and CHARLOTTESVILLE, Va., Dec. 15 /PRNewswire-FirstCall/ ... and the University of Virginia (UVa) in ... into a strategic research collaboration to enhance ... artery disease (CAD) with a secondary focus ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The collaborative ...
(Date:12/15/2009)... The Center for Business Intelligence (CBI), a ... announce the full agenda for the ... . The forum will take place at ... ,, Over 1,500 senior-level Finance, Accounting, Audit ... event since its inception, and this year,s ...
(Date:12/15/2009)... Prinz Law Office has announced the launch of several ... secure legal services in the current economic climate. ... the opportunity to finance legal services over a period ... any equity in their start-up companies. The second ... fixed montly payment arrangements over 6 to 12 month ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... With the FDA for the Fourth Genmab Antibody ... Company,s Collaboration with Roche., COPENHAGEN, December 12 ... Drug application (IND) for a,Genmab antibody developed under the ... by Roche. Genentech and Roche are collaborating on,development of ...
... EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the independent Data ... Company,s on-going MAESTRO-03 U.S. pivotal phase III,clinical trial ... MS and,recommended that the trial continue., This ...
... Lucid, Inc., (http://www.lucid-tech.com ), a leading U.S. ... Stahel as Director, Asia Pacific Region., Based ... newly created,position based on his extensive medical technology ... in the development of medical,technology and pre-cancer and ...
Other Biology Technology:Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region 2
(Date:12/16/2009)... rituals can help them get psyched up for contests, ... which many athletes gobble down before and during events, ... "These agents are treatments for the symptoms of an ... research at Indiana University focuses on musculoskeletal health and ... or train at a certain level, but pain occurs ...
(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...
(Date:12/16/2009)... IgeaCare Solutions Inc. is pleased to ... healthcare communications company previously operating as IgeaCare Systems ... move forward under new leadership and funding. ,, ... to the position of Chief Executive Officer. Under ... providing a superior servicing and support model; fast ...
Breaking Biology News(10 mins):NSAIDs: Take 'em early and often when competing? Think again 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2New IVF Software MedITEX to be Presented at the ESHRE Exhibition 12663 1New IVF Software MedITEX to be Presented at the ESHRE Exhibition 12663 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 1Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 3Inoperable Colon Cancer Responds to New Treatment 49145 1Inoperable Colon Cancer Responds to New Treatment 49145 2
... University of Missouri suggests that eating a certain form ... the prostate cancer-fighting potential of the tomato. The positive ... studies, but, until now, researchers did not know exactly ... greatest protective effect from tomatoes comes from rehydrating tomato ...
... core, why are there magnetic anomalies in rocks, how ... grow? These and many other important questions the mineral ... EuroMinScI (European Mineral Sciences Initiative) Conference held in Giens, ... event of the EuroMinScI Community, providing a venue for ...
... 29th May, a report setting out a "comprehensive and ... presented by the report,s author Mr. Pavan Sukhdev. The ... of Germany and Stavros Dimas the Commissioner responsible for ... understanding of the true economic value of the benefits ...
Other Biology News:Young mineral scientists rock! 2Young mineral scientists rock! 3Young mineral scientists rock! 4The Economics of Ecosystems and Biodiversity- TEEB 2The Economics of Ecosystems and Biodiversity- TEEB 3The Economics of Ecosystems and Biodiversity- TEEB 4The Economics of Ecosystems and Biodiversity- TEEB 5